NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72143-0231-30 | 72143-0231 | ISOTRETINOIN | ACCUTANE | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan 11, 2021 | Dec 31, 2023 | No Longer Used |
70710-1022-08 | 70710-1022 | Isotretinoin | Isotretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 12, 2023 | In Use | |
00555-1056-86 | 00555-1056 | Isotretinoin | Claravis | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 18, 2006 | In Use | |
73190-0999-01 | 73190-0999 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov 21, 2024 | In Use | |
00378-6614-85 | 00378-6614 | Isotretinoin | Amnesteem | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 11, 2015 | In Use | |
68308-0575-30 | 68308-0575 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 3, 2021 | In Use | |
70771-1558-08 | 70771-1558 | Isotretinoin | Isotretinoin | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 12, 2023 | In Use | |
69238-2088-06 | 69238-2088 | Bexarotene | Bexarotene | 10.0 mg/g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | May 4, 2022 | In Use | |
54868-5041-00 | 54868-5041 | Isotretinoin | Amnesteem | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 14, 2009 | In Use | |
00004-0169-49 | 00004-0169 | Isotretinoin | Accutane | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | May 7, 1982 | Dec 22, 2010 | No Longer Used | ||
70771-1557-04 | 70771-1557 | Isotretinoin | Isotretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 12, 2023 | In Use | |
10631-0133-31 | 10631-0133 | Isotretinoin | Absorica | 25.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Feb 17, 2015 | In Use | |
61748-0303-13 | 61748-0303 | Isotretinoin | Myorisan | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Aug 26, 2015 | In Use | |
57664-0022-97 | 57664-0022 | Isotretinoin | Isotretinoin | 25.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec 29, 2020 | In Use | |
55111-0113-78 | 55111-0113 | Isotretinoin | ZENATANE | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Mar 9, 2015 | In Use | |
10631-0002-31 | 10631-0002 | isotretinoin | Absorica LD | 8.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov 20, 2019 | In Use | |
69189-0464-01 | 69189-0464 | Tretinoin | Tretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan 8, 2016 | May 24, 2017 | No Longer Used |
75929-0174-03 | 75929-0174 | Belumosudil | Rezurock | 200.0 mg/1 | Chemotherapy | Rho Kinase Inhibitor | ROCK 1, ROCK2 | Oral | Jul 16, 2021 | In Use | |
79802-0200-30 | 79802-0200 | belumosudil | Rezurock | 200.0 mg/1 | Chemotherapy | Rho Kinase Inhibitor | ROCK 1, ROCK2 | Oral | Jul 16, 2021 | In Use | |
00003-4160-60 | 00003-4160 | Repotrectinib | Augtyro | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Nov 1, 2024 | In Use | |
00003-4160-14 | 00003-4160 | Repotrectinib | Augtyro | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Nov 1, 2024 | In Use | |
00003-4040-60 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec 5, 2023 | In Use | |
00003-4040-12 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec 5, 2023 | In Use | |
57902-0860-03 | 57902-0860 | Samarium SM 153 Lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
11994-0016-01 | 11994-0016 | samarium Sm 153 lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use |
Found 11120 results — Export these results